Is Aptinyx (APTX) a Sell? What does JPMorgan Think?

July 16, 2018 - By Margaret Guttierez

Why Has JPMorgan Given Aptinyx (APTX) a $30.0 Price Target

Stock research analysts at JPMorgan has initiated coverage on Aptinyx (APTX) with a key Overweight rating. The price target for APTX is $30.0. It suggests a possible upside of 45.63 % from company’s stock close price.

The stock decreased 2.23% or $0.47 during the last trading session, reaching $20.6. About 72,006 shares traded. Aptinyx Inc. (APTX) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company has market cap of $690.02 million. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. It currently has negative earnings. The firm has a collaboration agreement with Allergan plc.

More notable recent Aptinyx Inc. (NASDAQ:APTX) news were published by: Seekingalpha.com which released: “Aptinyx Proposes Final Terms For $80 Million IPO” on June 18, 2018, also Streetinsider.com with their article: “BMO Capital Starts Aptinyx (APTX) at Outperform” published on July 16, 2018, 247Wallst.com published: “IPO News This Week: A Record 12 IPOs Coming to Market” on June 24, 2018. More interesting news about Aptinyx Inc. (NASDAQ:APTX) were released by: Seekingalpha.com and their article: “Aptinyx IPO: It Collaborated With Allergan, But Shares Are Not Cheap” published on June 27, 2018 as well as Streetinsider.com‘s news article titled: “Cowen Starts Aptinyx (APTX) at Outperform” with publication date: July 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.